Johan Pluvy

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

Sandra Assoun, Nathalie Théou–Anton, Marina Nguenang et al. · Lung Cancer · 2019 · 166 citations · Full text

Cancer Immunosurveillance, Medicine, Immune Checkpoint Inhibitors +9

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Guillaume Manson, Alexandre Maria, F. Poizeau et al. · Journal for ImmunoTherapy of Cancer · 2019 · 102 citations · Full text

Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study

Raphaël Borie, Laurent Savale, Antoine Dossier et al. · PLoS ONE · 2020 · 20 citations · Full text

Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors

Baptiste Abbar, Victoire de Castelbajac, Paul Gougis et al. · Lung Cancer · 2020 · 17 citations · Full text